In the neoadjuvant phase, grade ≥ 3 treatment-related adverse events (TRAEs) occurred in only 1 patient (3%), which was a case of grade 3 asthenia. Standard chemoradiation was administered 5 to 8 weeks after the start of the neoadjuvant phase. Following chemoradiation, patients received maintenance nivolumab (480 mg every 4 weeks) for 6 months. Mandatory tumor biopsies were collected at baseline (before ICB) and after the neoadjuvant phase (before chemoradiation). Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.